Pros and cons of GnRHa treatment for early puberty in girls

Nature Reviews Endocrinology

Volumn 10, Issue 6, 2014, Pages 352-363

  Willemsen, Ruben H ^a   Elleri, Daniela ^a   Williams, Rachel M ^a   Ong, Ken K ^b   Dunger, David B ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE;

ADULT DISEASE; AGE; BODY COMPOSITION; BODY HEIGHT; BONE DENSITY; BREAST CANCER; BREAST DEVELOPMENT; FAMILY HISTORY; FEMALE; FOLLITROPIN BLOOD LEVEL; GENE EXPRESSION; GENETIC ASSOCIATION; GENOME ANALYSIS; GONADORELIN TEST; GONADOTROPIN RELEASE; GROWTH; GROWTH ACCELERATION; HIGH RISK BEHAVIOR; HORMONAL THERAPY; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS FUNCTION; LIFESTYLE MODIFICATION; LUTEINIZING HORMONE BLOOD LEVEL; MENARCHE; METABOLIC SYNDROME X; OBESITY; OVARY CYST; PATHOPHYSIOLOGY; PRADER WILLI SYNDROME; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PUBERTY; REPRODUCTION; REVIEW; SEXUAL BEHAVIOR; SOCIAL PSYCHOLOGY; SOCIAL STATUS; THERAPY EFFECT;

ADOLESCENT; AFRICAN AMERICANS; BODY COMPOSITION; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GONADOTROPIN-RELEASING HORMONE; GROWTH; HORMONE ANTAGONISTS; HUMANS; PUBERTY, PRECOCIOUS; REPRODUCTION; RISK FACTORS; SOCIAL BEHAVIOR;

EID: 84901354208     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.40     Document Type: Review

References (135)

1. Gluckman, P. D. & Hanson, M. A. Evolution, development and timing of puberty. Trends Endocrinol. Metab. 17, 7-12 (2006).
2. Parent, A. S. et al. The timing of normal puberty and the age limits of sexual precocity: Variations around the world, secular trends, and changes after migration. Endocr. Rev. 24, 668-693 (2003).
3. Lehmann, A., Scheffler, C. & Hermanussen, M. The variation in age at menarche: An indicator of historic developmental tempo. Anthropol. Anz. 68, 85-99 (2010).
4. Cole, T. J. Secular trends in growth. Proc. Nutr. Soc. 59, 317-324 (2000).
5. Morris, D. H., Jones, M. E., Schoemaker, M. J., Ashworth, A. & Swerdlow, A. J. Secular trends in age at menarche in women in the UK born 1908-1993: Results from the Breakthrough Generations Study. Paediatr. Perinat. Epidemiol. 25, 394-400 (2011).
6. Marshall, W. A. & Tanner, J. M. Variations in pattern of pubertal changes in girls. Arch. Dis. Child. 44, 291-303 (1969).
7. Herman-Giddens, M. E. et al. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the Pediatric Research in Office Settings network. Pediatrics 99, 505-512 (1997).
8. Biro, F. M. et al. Onset of breast development in a longitudinal cohort. Pediatrics 132, 1019-1027 (2013).
9. Herman-Giddens, M. E. et al. Secondary sexual characteristics in boys: Data from the Pediatric Research in Office Settings Network. Pediatrics 130, e1058-e1068 (2012).
10. Han, J. C., Lawlor, D. A. & Kimm, S. Y. Childhood obesity. Lancet 375, 1737-1748 (2010).
11. Wagner, I. V. et al. Effects of obesity on human sexual development. Nat. Rev. Endocrinol. 8, 246-254 (2012).
12. Ahmed, M. L., Ong, K. K. & Dunger, D. B. Childhood obesity and the timing of puberty. Trends Endocrinol. Metab. 20, 237-242 (2009).
13. Aksglaede, L., Juul, A., Olsen, L. W. & Sorensen, T. I. Age at puberty and the emerging obesity epidemic. PLoS ONE 4, e8450 (2009).
14. Carel, J. C. et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3 month depot (11.25 mg). J. Clin. Endocrinol. Metab. 87, 4111-4116 (2002).
15. Lee, P. A. et al. Efficacy and safety of leuprolide acetate 3 month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J. Clin. Endocrinol. Metab. 97, 1572-1580 (2012).
16. Neely, E. K. et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J. Pediatr. 121, 634-640 (1992).
17. Largo, R. H. & Prader, A. Pubertal development in Swiss girls. Helv. Paediatr. Acta 38, 229-243 (1983).
18. Roche, A. F., Wellens, R., Attie, K. M. & Siervogel, R. M. The timing of sexual maturation in a group of US white youths. J. Pediatr. Endocrinol. Metab. 8, 11-18 (1995).
19. Juul, A. et al. Pubertal development in Danish children: Comparison of recent European and US data. Int. J. Androl. 29, 247-255 (2006).
20. Dattani, M. T., Tziaferi, V. & Hindmarsh, P. C. in Brook's Clinical Pediatric Endocrinology 6th edn (eds Brook, C. G. D., Clayton, P. E. & Brown, R. S.) 213-216 (2009).
21. Garibaldi, L. & Chemaitilly, W. in Nelson Textbook of Pediatrics 19th edn (eds Kliegman, R. M., Stanton, B. F., St. Geme, J. W., Schor, N. F. & Behrman, R. E.) 1887 (2011).
22. Kaplowitz, P. B. & Oberfield, S. E. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 104, 936-941 (1999).
23. Midyett, L. K., Moore, W. V. & Jacobson, J. D. Are pubertal changes in girls before age 8 benigñ Pediatrics 111, 47-51 (2003).
24. Ritzen, E. M. Early puberty: What is normal and when is treatment indicated? Horm. Res. 60 (Suppl. 3), 31-34 (2003).
25. Mul, D., Oostdijk, W. & Drop, S. L. Early puberty in girls. Best Pract. Res. Clin. Endocrinol. Metab. 16, 153-163 (2002).
26. Carel, J. C. et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123, e752-e762 (2009).
27. Sorensen, K. et al. Recent secular trends in pubertal timing: Implications for evaluation and diagnosis of precocious puberty. Horm. Res. Paediatr. 77, 137-145 (2012).
28. Lumbroso, S., Paris, F., Sultan, C. & European Collaborative Study. Activating Gsα mutations: Analysis of 113 patients with signs of McCune-Albright syndrome-A European Collaborative Study. J. Clin. Endocrinol. Metab. 89, 2107-2113 (2004).
29. Stanhope, R., Abdulwahid, N. A., Adams, J. & Brook, C. G. Studies of gonadotrophin pulsatility and pelvic ultrasound examinations distinguish between isolated premature thelarche and central precocious puberty. Eur. J. Pediatr. 145, 190-194 (1986).
30. Pescovitz, O. H., Hench, K. D., Barnes, K. M., Loriaux, D. L. & Cutler, G. B. Jr. Premature thelarche and central precocious puberty: The relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone. J. Clin. Endocrinol. Metab. 67, 474-479 (1988).
31. Traggiai, C. & Stanhope, R. Disorders of pubertal development. Best Pract. Res. Clin. Obstet. Gynaecol. 17, 41-56 (2003).
32. Mogensen, S. S. et al. Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J. Clin. Endocrinol. Metab. 96, 1393-1401 (2011).
33. Toppari, J. & Juul, A. Trends in puberty timing in humans and environmental modifiers. Mol. Cell Endocrinol. 324, 39-44 (2010).
34. Mul, D., Oostdijk, W. & Drop, S. L. Early puberty in adopted children. Horm. Res. 57, 1-9 (2002).
35. Soriano-Guillen, L. et al. Central precocious puberty in children living in Spain: Incidence, prevalence, and influence of adoption and immigration. J. Clin. Endocrinol. Metab. 95, 4305-4313 (2010).
36. Teilmann, G., Pedersen, C. B., Skakkebaek, N. E. & Jensen, T. K. Increased risk of precocious puberty in internationally adopted children in Denmark. Pediatrics 118, e391-e399 (2006).
37. Kaprio, J. et al. Common genetic influences on BMI and age at menarche. Hum. Biol. 67, 739-753 (1995).
38. de Vries, L., Kauschansky, A., Shohat, M. & Phillip, M. Familial central precocious puberty suggests autosomal dominant inheritance. J. Clin. Endocrinol. Metab. 89, 1794-1800 (2004).
39. Elks, C. E. et al. Thirty new loci for age at menarche identified by a meta-Analysis of genome-wide association studies. Nat. Genet. 42, 1077-1085 (2010).
40. Silveira, L. F. & Latronico, A. C. Approach to the patient with hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 98, 1781-1788 (2013).
41. Silveira, L. G. et al. Mutations of the KISS1 gene in disorders of puberty. J. Clin. Endocrinol. Metab. 95, 2276-2280 (2010).
42. Teles, M. G. et al. A GPR54-Activating mutation in a patient with central precocious puberty. N. Engl. J. Med. 358, 709-715 (2008).
43. Abreu, A. P. et al. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N. Engl. J. Med. 368, 2467-2475 (2013).
44. Lomniczi, A. et al. Epigenetic control of female puberty. Nat. Neurosci. 16, 281-289 (2013).
45. Adan, L., Chemaitilly, W., Trivin, C. & Brauner, R. Factors predicting adult height in girls with idiopathic central precocious puberty: Implications for treatment. Clin. Endocrinol. (Oxf.) 56, 297-302 (2002).
46. Bertelloni, S., Baroncelli, G. I., Sorrentino, M. C., Perri, G. & Saggese, G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur. J. Pediatr. 157, 363-367 (1998).
47. Leger, J., Reynaud, R & Czernichow, P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J. Pediatr. 137, 819-825 (2000).
48. Palmert, M. R., Malin, H. V. & Boepple, P. A. Unsustained or slowly progressive puberty in young girls: Initial presentation and long-Term follow-up of 20 untreated patients. J. Clin. Endocrinol. Metab. 84, 415-423 (1999).
49. Job, J. C. & Canlorbe, P. in Pediatric Endocrinology (eds Job, J. C. & Pierson, M.) 406 (1981).
50. Plotnick, L. P. in Principles and Practice of Pediatrics (eds Oski, F. A., DeAngelis, C. D., Feigin, R. D. & Warshaw, J. B.) 1800 (1990).
51. Sorgo, W. et al. The effects of cyproterone acetate on statural growth in children with precocious puberty. Acta Endocrinol. (Copenh.) 115, 44-56 (1987).
52. Tena-Sempere, M. Deciphering puberty: Novel partners, novel mechanisms. Eur. J. Endocrinol. 167, 733-747 (2012).
53. Belchetz, P. E., Plant, T. M., Nakai, Y., Keogh, E. J. & Knobil, E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202, 631-633 (1978).
54. Davies, T. F. et al. Reduced 'gonadotrophin response to releasing hormone' after chronic administration to impotent men. Clin. Endocrinol. (Oxf.) 6, 213-218 (1977).
55. Crowley, W. F. Jr. et al. Therapeutic use of pituitary desensitization with a long-Acting LHRH agonist: A potential new treatment for idiopathic precocious puberty. J. Clin. Endocrinol. Metab. 52, 370-372 (1981).
56. Parker, K. L. & Lee, P. A. Depot leuprolide acetate for treatment of precocious puberty. J. Clin. Endocrinol. Metab. 69, 689-691 (1989).
57. Antoniazzi, F. et al. Final height in girls with central precocious puberty: Comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr. 83, 1052-1056 (1994).
58. Johnson, S. R. et al. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty. J. Paediatr. Child. Health 48, E136-E139 (2012).
59. Miller, B. S. & Shukla, A. R. Sterile abscess formation in response to two separate branded long-Acting gonadotropin-releasing hormone agonists. Clin. Ther. 32, 1749-1751 (2010).
60. Lam, C., Tjon, J., Hamilton, J. & Ahmet, A. H. Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: Case report and review of the literature. Pharmacotherapy 26, 1811-1815 (2006).
61. Roger, M. et al. Long term treatment of male and female precocious puberty by periodic administration of a long-Acting preparation of D Trp6 luteinizing hormone-releasing hormone microcapsules. J. Clin. Endocrinol. Metab. 62, 670-677 (1986).
62. Yeshaya, A. et al. Prolonged vaginal bleeding during central precocious puberty therapy with a long-Acting gonadotropin-releasing hormone agonist. Acta Obstet. Gynecol. Scand. 77, 327-329 (1998).
63. Oostdijk, W. et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch. Dis. Child. 75, 292-297 (1996).
64. Carel, J. C. et al. Final height after long-Term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J. Clin. Endocrinol. Metab. 84, 1973-1978 (1999).
65. Arrigo, T. et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur. J. Endocrinol. 141, 140-144 (1999).
66. DiMartino-Nardi, J., Wu, R., Fishman, K. & Saenger, P. The effect of long-Acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty. J. Clin. Endocrinol. Metab. 73, 902-906 (1991).
67. Weise, M., Flor, A., Barnes, K. M., Cutler, G. B. Jr & Baron, J. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. J. Clin. Endocrinol. Metab. 89, 103-107 (2004).
68. Giustina, A. & Veldhuis, J. D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717-797 (1998).
69. Harris, D. A. et al. Somatomedin C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist. J. Clin. Endocrinol. Metab. 61, 152-159 (1985).
70. Mansfield, M. J. et al. Changes in growth and serum growth hormone and plasma somatomedin C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J. Clin. Endocrinol. Metab. 66, 3-9 (1988).
71. Stanhope, R., Pringle, P. J. & Brook, C. G. Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue. Acta Paediatr. Scand. 77, 525-530 (1988).
72. Juul, A. et al. Serum insulin-like growth factor I (IGF I) and IGF-binding protein 3 levels are increased in central precocious puberty: Effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate). J. Clin. Endocrinol. Metab. 80, 3059-3067 (1995).
73. Verrotti, A., Ferrari, M., Sabatino, G., Morgese, G. & Chiarelli, F. Serum insulin-like growth factor I (IGF I) and IGF binding protein 3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate. Gynecol. Endocrinol. 11, 243-250 (1997).
74. Galluzzi, F., Salti, R., Bindi, G., Pasquini, E. & La Cauza, C. Adult height comparison between boys and girls with precocious puberty after long-Term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr. 87, 521-527 (1998).
75. Sklar, C. A. et al. Suppression of the pituitary-gonadal axis in children with central precocious puberty: Effects on growth, growth hormone, insulin-like growth factor I, and prolactin secretion. J. Clin. Endocrinol. Metab. 73, 734-738 (1991).
76. Carel, J. C., Lahlou, N., Roger, M. & Chaussain, J. L. Precocious puberty and statural growth. Hum. Reprod. Update 10, 135-147 (2004).
77. Biro, F. M. et al. Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung, and Blood Institute Growth and Health Study. J. Pediatr. 138, 636-643 (2001).
78. Bayley, N. & Pinneau, S. R. Tables for predicting adult height from skeletal age: Revised for use with the Greulich-Pyle hand standards. J. Pediatr. 40, 423-441 (1952).
79. Bouvattier, C. et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: A randomized long-Term pilot study. J. Clin. Endocrinol. Metab. 84, 3575-3578 (1999).
80. Cassio, A., Cacciari, E., Balsamo, A., Bal, M. & Tassinari, D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch. Dis. Child. 81, 329-332 (1999).
81. Heger, S., Partsch, C. J. & Sippell, W. G. Long-Term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function. J. Clin. Endocrinol. Metab. 84, 4583-4590 (1999).
82. Kempers, M. J. & Otten, B. J. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height. Eur. J. Endocrinol. 147, 609-616 (2002).
83. Klein, K. O., Barnes, K. M., Jones, J. V., Feuillan, P. P. & Cutler, G. B. Jr. Increased final height in precocious puberty after long-Term treatment with LHRH agonists: The National Institutes of Health experience. J. Clin. Endocrinol. Metab. 86, 4711-4716 (2001).
84. Lazar, L., Padoa, A. & Phillip, M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J. Clin. Endocrinol. Metab. 92, 3483-3489 (2007).
85. Pasquino, A. M. et al. Long-Term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. J. Clin. Endocrinol. Metab. 93, 190-195 (2008).
86. Tanaka, T. et al. Results of long-Term follow-up after treatment of central precocious puberty with leuprorelin acetate: Evaluation of effectiveness of treatment and recovery of gonadal function. The TAP 144 SR Japanese Study Group on Central Precocious Puberty. J. Clin. Endocrinol. Metab. 90, 1371-1376 (2005).
87. Allali, S. et al. Predicting the adult height of girls with central precocious puberty. Med. Sci. Monit. 17, PH41-PH48 (2011).
88. Lee, P. A. et al. Efficacy of leuprolide acetate 1 month depot for central precocious puberty (CPP): Growth outcomes during a prospective, longitudinal study. Int. J. Pediatr. Endocrinol. 2011, 7 (2011).
89. Park, H. K. et al. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin. Endocrinol. (Oxf.) 77, 743-748 (2012).
90. Arrigo, T. et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur. J. Endocrinol. 150, 533-537 (2004).
91. van der Sluis, I. M., Boot, A. M., Krenning, E. P., Drop, S. L. & de Muinck Keizer-Schrama, S. M. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J. Clin. Endocrinol. Metab. 87, 506-512 (2002).
92. Palmert, M. R. et al. Is obesity an outcome of gonadotropin-releasing hormone agonist administratioñ Analysis of growth and body composition in 110 patients with central precocious puberty. J. Clin. Endocrinol. Metab. 84, 4480-4488 (1999).
93. Boot, A. M., De Muinck Keizer-Schrama, S., Pols, H. A., Krenning, E. P. & Drop, S. L. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J. Clin. Endocrinol. Metab. 83, 370-373 (1998).
94. Antoniazzi, F. et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J. Clin. Endocrinol. Metab. 88, 1096-1101 (2003).
95. Traggiai, C. et al. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: Effects on body mass index and final height. Eur. J. Endocrinol. 153, 463-464 (2005).
96. Neely, E. K. et al. Bone mineral density during treatment of central precocious puberty. J. Pediatr. 127, 819-822 (1995).
97. Antoniazzi, F. et al. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment. J. Clin. Endocrinol. Metab. 84, 1992-1996 (1999).
98. Alessandri, S. B. et al. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist. Clinics (Sao Paulo) 67, 591-596 (2012).
99. Kapteijns-van Kordelaar, S., Noordam, K., Otten, B. & van den Bergh, J. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature. Eur. J. Pediatr. 162, 776-780 (2003).
100. Bertelloni, S., Baroncelli, G. I., Ferdeghini, M., Menchini-Fabris, F. & Saggese, G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur. J. Pediatr. 159, 369-374 (2000).
101. Jensen, A. M., Brocks, V., Holm, K., Laursen, E. M. & Muller, J. Central precocious puberty in girls: Internal genitalia before, during, and after treatment with long-Acting gonadotropin-releasing hormone analogues. J. Pediatr. 132, 105-108 (1998).
102. Lazar, L., Meyerovitch, J., de Vries, L., Phillip, M. & Lebenthal, Y. Treated and untreated women with idiopathic precocious puberty: Long-Term follow-up and reproductive outcome between the third and fifth decades. Clin. Endocrinol. (Oxf.) 80, 570-576 (2014).
103. Arrigo, T. et al. Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment. Eur. J. Pediatr. 166, 73-74 (2007).
104. Feuillan, P. P., Jones, J. V., Barnes, K., Oerter-Klein, K. & Cutler, G. B. Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J. Clin. Endocrinol. Metab. 84, 44-49 (1999).
105. Manasco, P. K. et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J. Clin. Endocrinol. Metab. 67, 368-372 (1988).
106. Schroor, E. J., Van Weissenbruch, M. M. & Delemarre-van de Waal, H. A. Long-Term GnRH-Agonist treatment does not postpone central development of the GnRH pule generator in girls with idiopathic precocious puberty. J. Clin. Endocrinol. Metab. 80, 1696-1701 (1995).
107. Ben-Haroush, A., Goldberg-Stern, H., Phillip, M. & de Vries, L. GnRH agonist treatment in girls with precocious puberty does not compromise post-pubertal uterine size. Hum. Reprod. 22, 895-900 (2007).
108. van Noord, P. A., Dubas, J. S., Dorland, M., Boersma, H. & te Velde, E. Age at natural menopause in a population-based screening cohort: The role of menarche, fecundity, and lifestyle factors. Fertil. Steril. 68, 95-102 (1997).
109. Kato, I. et al. Prospective study of factors influencing the onset of natural menopause. J. Clin. Epidemiol. 51, 1271-1276 (1998).
110. Heger, S. et al. Long-Term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol. Cell Endocrinol. 254-255, 217-220 (2006).
111. Cassio, A. et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: Long-Term results of a randomized trial in adults. J. Pediatr. 149, 532-536 (2006).
112. Magiakou, M. A. et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: A single center, long-Term follow-up study. J. Clin. Endocrinol. Metab. 95, 109-117 (2010).
113. Franceschi, R. et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil. Steril. 93, 1185-1191 (2010).
114. Michelmore, K. F., Balen, A. H., Dunger, D. B. & Vessey, M. P. Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.) 51, 779-786 (1999).
115. Ong, K. K. et al. Infancy weight gain predicts childhood body fat and age at menarche in girls. J. Clin. Endocrinol. Metab. 94, 1527-1532 (2009).
116. Thankamony, A. et al. Higher levels of IGF I and adrenal androgens at age 8 years are associated with earlier age at menarche in girls. J. Clin. Endocrinol. Metab. 97, E786-E790 (2012).
117. Michaud, P. A., Suris, J. C. & Deppen, A. Gender-related psychological and behavioural correlates of pubertal timing in a national sample of Swiss adolescents. Mol. Cell Endocrinol. 254-255, 172-178 (2006).
118. Tremblay, L. & Frigon, J. Y. Precocious puberty in adolescent girls: A biomarker of later psychosocial adjustment problems. Child. Psychiatry Hum. Dev. 36, 73-94 (2005).
119. Gaudineau, A. et al. Factors associated with early menarche: Results from the French Health Behaviour in School-Aged Children (HBSC) study. BMC Public Health 10, 175 (2010).
120. Carter, R., Jaccard, J., Silverman, W. K. & Pina, A. A. Pubertal timing and its link to behavioral and emotional problems among 'at-risk' African American adolescent girls. J. Adolesc. 32, 467-481 (2009).
121. Carter, R., Silverman, W. K. & Jaccard, J. Race and perceived pubertal transition effects on girls' depressive symptoms and delinquent behaviors. J. Youth Adolesc. 42, 1155-1168 (2013).
122. Williams, J. M. & Dunlop, L. C. Pubertal timing and self-reported delinquency among male adolescents. J. Adolesc. 22, 157-171 (1999).
123. Ehrhardt, A. A. & Meyer-Bahlburg, H. F. Idiopathic precocious puberty in girls: Long-Term effects on adolescent behavior. Acta Endocrinol. Suppl. (Copenh.) 279, 247-253 (1986).
124. Schoevaart, C. E., Drop, S. L., Otten, B. J., Slijper, F. M. & Degenhart, H. J. Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty. Horm. Res. 34, 197-203 (1990).
125. Mul, D. et al. Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr. 90, 965-971 (2001).
126. Xhrouet-Heinrichs, D. et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-Acting triptorelin therapy. Acta Paediatr. 86, 808-815 (1997).
127. Stoll, B. A., Vatten, L. J. & Kvinnsland, S. Does early physical maturity influence breast cancer risk? Acta Oncol. 33, 171-176 (1994).
128. Britt, K. Menarche, menopause, and breast cancer risk. Lancet Oncol. 13, 1071-1072 (2012).
129. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-Analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13, 1141-1151 (2012).
130. Madigan, M. P. et al. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control 9, 199-207 (1998).
131. Lakshman, R. et al. Early age at menarche associated with cardiovascular disease and mortality. J. Clin. Endocrinol. Metab. 94, 4953-4960 (2009).
132. Prentice, P. & Viner, R. M. Pubertal timing and adult obesity and cardiometabolic risk in women and men: A systematic review and meta-Analysis. Int. J. Obes. (Lond.) 37, 1036-1043 (2013).
133. Elks, C. E. et al. Age at menarche and type 2 diabetes risk: The EPIC-InterAct study. Diabetes Care 36, 3526-3534 (2013).
134. Sorensen, K., Mouritsen, A., Mogensen, S. S., Aksglaede, L. & Juul, A. Insulin sensitivity and lipid profiles in girls with central precocious puberty before and during gonadal suppression. J. Clin. Endocrinol. Metab. 95, 3736-3744 (2010).
135. Ibañez, L., Valls, C., Ong, K., Dunger, D. B. & de Zegher, F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: A randomized study in low birth weight girls with early-normal onset of puberty. J. Clin. Endocrinol. Metab. 91, 2068-2073 (2006).